**Supplementary Material**

**Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer’s Disease and Other Dementia Disorders**

**Supplementary Table 1.** Secondary stroke prevention in dementia subtypes prior to stroke and at discharge from hospital

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Prior to Stroke** | | | | | **Initiation Planned at Discharge** | | | | |
|  | **AD n=332** | **Mixed n=332** | **Vascular n=325** | **All other n=421** | **p** | **AD  n=300** | **Mixed n=288** | **Vascular  n=280** | **All other n=373** | **p** |
| **Age, mean (SD)** | 82 (6.7) | 83 (5.5) | 82 (7.1) | 83 (6.7) | 0.057 | 82 (6.8) | 83 (5.5) | 81 (7.1) | 83 (6.7) | **0.002** |
| **Female sex** | 210 (63.3) | 180 (54.2) | 158 (48.6) | 247 (58.7) | **0.001** | 190 (63.3) | 154 (53.5) | 131 (46.8) | 218 (58.4) | **<0.001** |
| **Antiplatelets** | 133 (40.1) | 177 (53.3) | 169 (52.0) | 195 (46.3) | **0.002** | 230 (77.4) | 222 (77.6) | 203 (73.0) | 297 (80.9) | 0.129 |
| **in AF** | 56 (60.9) | 78 (60.9) | 69 (55.2) | 69 (51.9) | 0.398 | 54 (55.7) | 68 (58.1) | 50 (50.5) | 72 (60.5) | 0.498 |
| **in non-AF** | 77 (32.1) | 99 (48.5) | 100 (50.0) | 126 (43.8) | **<0.001** | 176 (88.0) | 154 (91.1) | 151 (85.3) | 225 (90.7) | 0.244 |
| **Anticoagulants in AF** | 11 (12.0) | 17 (13.3) | 19 (15.2) | 13 (9.8) | 0.610 | 34 (35.1) | 31 (26.7) | 41 (41.8) | 26 (21.8) | **0.008** |
| **BPLM** | 197 (59.3) | 214 (64.5) | 242 (74.5) | 277 (65.8) | **0.001** | 202 (68.2) | 197 (68.9) | 233 (83.8) | 265 (72.2) | **<0.001** |
| **Statins** | 56 (16.9) | 59 (17.8) | 70 (21.5) | 74 (17.6) | 0.402 | 134 (45.3) | 127 (44.4) | 126 (45.5) | 153 (41.7) | 0.740 |

Data are represented as number of cases (n) and percentage proportion (%), if not stated otherwise. In variables where n (%) are reported, p-values were obtained by chi-square, whereas in variables where mean (SD) are reported, p-values were obtained by ANOVA.  
Patients who did not survive until the follow-up are excluded. Therapy was registered if a patient collected at least one prescription from the pharmacy in the 6-month period before the stroke, or 1st, 2nd, and 3rd year after stroke event.  
AD, Alzheimer’s disease; Mixed, mixed dementia; Vascular, vascular dementia;BPLM, blood pressure lowering medication; AF, atrial fibrillation

**Supplementary Table 2.** Secondary stroke prevention in dementia subtypes 1st, 2nd, and 3rd year after stroke

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **1-Year Post-Stroke** | | | | | **2-Years Post-Stroke** | | | | | **3-Years Post-Stroke** | | | | |
|  | **AD  n=216** | **Mixed n=194** | **Vascular n=209** | **All other n=270** | **p** | **AD n=131** | **Mixed n=117** | **Vascular n=119** | **All other n=156** | **p** | **AD n=65** | **Mixed n=56** | **Vascular  n=63** | **All other n=83** | **p** |
| **Age, mean (SD)** | 82 (6.9) | 83 (5.5) | 81  (7.1) | 83  (7.0) | **0.034** | 83 (6.5) | 84 (5.1) | 82  (7.5) | 84  (9.9) | **0.035** | 82 (6.0) | 84 (4.5) | 82  (7.3) | 86  (7.4) | **0.001** |
| **Female sex** | 138 (63.9) | 103 (53.1) | 98  (46.9) | 162  (60.0) | **0.002** | 84 (64.1) | 64 (54.7) | 53  (44.5) | 99  (63.5) | **0.004** | 46 (70.8) | 33 (58.9) | 23  (36.5) | 55  (66.3) | **<0.001** |
| **Antiplatelets** | 149 (69.0) | 136 (70.1) | 139  (66.5) | 197  (73.0) | 0.487 | 92 (70.2) | 66 (56.4) | 78  (65.5) | 115  (73.7) | **0.020** | 43 (66.2) | 32 (57.1) | 38  (60.3) | 60  (72.3) | 0.252 |
| **in AF** | 27 (45.8) | 38 (55.1) | 28  (42.4) | 40  (52.6) | 0.423 | 13 (44.8) | 13 (33.3) | 14  (38.9) | 25  (61.0) | 0.075 | 7 (58.3) | 9 (45.0) | 5  (35.7) | 14  (66.7) | 0.274 |
| **in non-AF** | 121 (77.6) | 97 (78.2) | 108  (77.1) | 156  (81.3) | 0.781 | 78 (77.2) | 53 (67.9) | 63  (76.8) | 89  (78.1) | 0.384 | 36 (67.9) | 23 (63.9) | 33  (67.3) | 46  (74.2) | 0.726 |
| **Anticoagulants in AF** | 22 (37.3) | 13 (18.8) | 17  (25.8) | 22  (28.9) | 0.132 | 7 (24.1) | 5 (12.8) | 12  (33.3) | 4  (9.8) | **0.038** | 2 (16.7) | 3 (15.0) | 6  (42.9) | 3  (14.3) | 0.212 |
| **BPLM** | 141 (65.3) | 116 (59.8) | 164  (78.5) | 191  (70.7) | **<0.001** | 80 (61.1) | 73 (62.4) | 94  (79.0) | 107  (68.6) | **0.011** | 39 (60.0) | 33 (58.9) | 46  (73.0) | 55  (66.3) | 0.328 |
| **Statins** | 85 (39.4) | 69 (35.6) | 84  (40.2) | 97  (35.9) | 0.673 | 41 (31.3) | 36 (30.8) | 46  (38.7) | 45  (28.8) | 0.357 | 20 (30.8) | 11 (19.6) | 17  (27.0) | 18  (21.7) | 0.451 |

Data are represented as number of cases (n) and percentage proportion (%), if not stated otherwise. In variables where n (%) are reported, p-values were obtained by chi-square or Fisher’s exact test, whereas in variables where mean (SD) are reported, p-values were obtained by ANOVA.  
Patients who did not survive until the follow-up are excluded. Therapy was registered if a patient collected at least one prescription from the pharmacy in the 6-month period before the stroke, or 1st, 2nd, and 3rd year after stroke event. AD, Alzheimer’s disease; Mixed, mixed dementia; Vascular, vascular dementia;BPLM, blood pressure lowering medication; AF, atrial fibrillation